Physician profile
Rafia Khalil
NPI 1114907912
$19,257.09
in general payments reported to CMS, 2019-2025
32 companies · $3,374 in 2025
The $3,374 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,795 · 2020: $1,469 · 2021: $1,760 · 2022: $1,720 · 2023: $2,158 · 2024: $2,983 · 2025: $3,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,113 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,112.54 |
| Education | $402.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,497.61 | 2019-2025 | |
| Janssen Biotech, INC. | $2,121.00 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $2,087.71 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $1,358.23 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $1,159.97 | 2019-2025 | Orencia |
| Pfizer INC. | $1,074.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $682.49 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $654.40 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $408.36 | 2020-2025 | |
| Sobi, INC | $336.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $303.23 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $298.87 | 2021-2025 | Saphnelo, Evusheld |
| Organon LLC | $245.78 | 2022-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $241.38 | 2024-2025 | Idacio, Tyenne |
| Lilly USA, LLC | $231.66 | 2019-2023 | Taltz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $218.68 | 2019-2025 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $189.28 | 2019-2025 | Opsumit, Uptravi |
| Aurinia Pharma U.S., INC. | $144.98 | 2022-2025 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $134.90 | 2019-2020 | |
| Genentech USA, INC. | $121.24 | 2019-2024 | Actemra |
| Mallinckrodt Enterprises LLC | $117.12 | 2019 | |
| Alexion Pharmaceuticals, INC. | $115.59 | 2019-2025 | Strensiq |
| Radius Health, INC. | $113.63 | 2020-2025 | Tymlos |
| Pacira Therapeutics, INC. | $107.92 | 2020 | |
| Mallinckrodt Hospital Products INC. | $69.13 | 2020-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $63.21 | 2019-2022 | |
| Fidia Pharma USA INC. | $62.46 | 2022-2024 | Triluron, Hymovis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.70 | 2020 | |
| Mylan Institutional INC. | $22.26 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $18.12 | 2020 | |
| Biocon Biologics INC | $17.29 | 2023 | Hulio |
| Bioventus LLC | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafia Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.